Adherence
The semaglutide 2.4 mg single-dose pen-injector (SPI) demonstrates high ease-of-use and acceptability, with the vast majority of participants finding it easy to use and training, and preferring it over daily oral medication.
If you are considering semaglutide 2.4 mg via the single-dose pen, expect it to be easy to use. Most users found the training simple and the injection process easy. While some initial use errors (like seeing liquid on the skin) can occur, they are common in the first few injections and tend to disappear with practice. The device is generally preferred over daily pills due to its weekly frequency and ease of use.
For almost all participants, site staff rated ease-of-training as ‘easy’/’very easy’. Similarly, most participants considered use of the SPI to be ‘easy’/‘very easy’. ... 79.5% of participants preferred the weekly SPI over a daily pill.
Why this rating
Data comes from a Phase III trial (STEP 8) with a substantial sample size (N=155 for the SPI subset) using validated patient-reported outcome instruments (IDEA).
Source
Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the <scp>STEP</scp> 8 phase <scp>III</scp> trial
Søren Snitker et al. · Diabetes Obesity and Metabolism · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →